COMPARISON OF ANTIEMETIC EFFICIENCY OF ONDANSETRON AND METOCLOPRAMIDE IN CANCER PATIENTS WHO TAKE NON-CISPLATIN CHEMOTHERAPY REGIMENS

The aim of this study was to compare the antiemetic efficiency of ondansetron and metoclopramide in cancer patients who take non-cisplatin chemotherapy regimens. Ondansetron and metoclopramide were given to 30 patients in alternating manner. Ondansetron 8 mg and metoclopramide 50 mg were administered by intravenous route in the first day of chemotherapy. At the end of study, 113 metoclopramide courses and 122 ondansetron courses were evaluated. The success rates of ondansetron and metoclopramide in preventing emesis were 95% and 88%, respectively (P=0.002). Ondansetron was found superior to metoclopramide for the prophylaxis of nausea and vomiting in cancer patients who take non-cisplatin chemotherapy regimens.